A5004417292- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- CAR-T cell therapy research
- Polyomavirus and related diseases
- Cancer Research and Treatments
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Histone Deacetylase Inhibitors Research
- Multiple Myeloma Research and Treatments
- Biomedical Ethics and Regulation
- Cancer therapeutics and mechanisms
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Renal Transplantation Outcomes and Treatments
- Immune Cell Function and Interaction
- Viral-associated cancers and disorders
- Cancer Treatment and Pharmacology
- Eosinophilic Disorders and Syndromes
- Immunotherapy and Immune Responses
- DNA Repair Mechanisms
- Cytomegalovirus and herpesvirus research
- HIV/AIDS drug development and treatment
- T-cell and B-cell Immunology
- PARP inhibition in cancer therapy
The University of Texas MD Anderson Cancer Center
2016-2025
National Clinical Research
2024
Soochow University
2024
John Wiley & Sons (United States)
2016
University of Chicago
2015
Rutgers, The State University of New Jersey
2015
Rutgers New Jersey Medical School
2015
VA New Jersey Health Care System
2015
Institute for Myeloma & Bone Cancer Research
2015
Nanjing Medical University
2015
PURPOSE To investigate the use of a nonmyeloablative fludarabine-based preparative regimen to produce sufficient immunosuppression allow engraftment allogeneic stem cells and induction graft-versus-leukemia/lymphoma (GVL) as primary treatment modality for patients with chronic lymphocytic leukemia (CLL) lymphoma. PATIENTS AND METHODS Fifteen were studied. Six in advanced refractory relapse, therapy had failed two patients. Patients CLL or low-grade lymphoma received fludarabine 90 150 mg/m2...
Poor engraftment due to low cell doses restricts the usefulness of umbilical-cord-blood transplantation. We hypothesized that would be improved by transplanting cord blood was expanded ex vivo with mesenchymal stromal cells.
Purpose The clinical safety and efficacy of intravenous busulfan fludarabine (IV Bu/Flu) myeloablative conditioning as well graft-versus-host disease (GVHD) prophylaxis with high-dose, post-transplantation cyclophosphamide (PTCy) have been demonstrated independently in several single-institutional studies. We hypothesized that combining these two promising approaches a multi-institutional study human leukocyte antigen (HLA) -matched bone marrow transplantation would provide low rates severe...
The availability of an i.v. form busulfan (Bu) has prompted investigation administration schedules other than the 4-times-daily dosage commonly used with oral Bu. We have studied allogeneic stem cell transplantation (SCT) preparative regimen comprising fludarabine (FLU) 50 mg/m2 on days -6 to -2 plus Bu 3.2 mg/kg daily in a 3-hour infusion -5 -2. was given 70 patients aged 15 64 years (median, 41 years) hematologic malignancy. Thirty-six (51%) had high-risk malignancy, 28 (40%) unrelated or...
PURPOSE To evaluate the feasibility of allogeneic peripheral-blood progenitor-cell (PBPC) transplantation and to assess graft-versus-tumor effects in patients with metastatic breast cancer. PATIENTS AND METHODS Ten cancer that involved liver or bone marrow were treated high-dose chemotherapy PBPC transplantation. The median age was 42 years (range, 29 55). number sites three one five). conditioning regimen cyclophosphamide (6,000 mg/m2), carmustine (BCNU; 450 thiotepa (720 mg/m2) (CBT...
Hepatic venoocclusive disease (HVOD) is a complication of allogeneic hematopoietic stem cell transplantation (HSCT) and well-recognized dose-limiting toxicity oral busulfan (Bu)-based preparative regimens. The unpredictable absorption Bu from the gastrointestinal (GI) tract hepatic first-pass effects have led to development an intravenous preparation (i.v. Bu). purpose this retrospective comparison was evaluate incidence rate HVOD 100-day mortality in patients treated with...
Complete bioavailability of i.v. busulfan (Bu) provides dose assurance by reducing the interdose and interpatient variability in Bu systemic exposure (Bu-SE) associated with oral formulation. We hypothesized that Bu-SE, represented area under plasma concentration versus time curve (AUC), would correlate treatment outcome after allogeneic hematopoietic stem cell transplantation (HSCT) for chronic myelogenous leukemia (CML). Therefore, we analyzed risk death, incidence regimen-related...
In this study, we evaluated the influence of nonmyeloablative and ablative conditioning regimens on occurrence acute chronic graft-versus-host disease (GVHD). One hundred thirty-seven patients undergoing matched-related sibling transplantations received same GVHD prophylaxis. Myeloablative included intravenous busulfan/cyclophosphamide (n=45) fludarabine/melphalan (n=29). Patients in group (n=63) fludarabine/idarubicin/cytarabine, cisplatin/fludarabine/idarubicin,...
PURPOSE This study was undertaken to evaluate the feasibility and therapeutic effect of high-dose chemoradiotherapy with autologous or allogeneic bone marrow transplantation (BMT) in patients advanced chronic lymphocytic leukemia (CLL) who relapse after fludarabine treatment. PATIENTS AND METHODS Twenty-two CLL received cyclophosphamide, total-body irradiation, BMT. Eleven relapsed BMT collected during a prior fludarabine-induced remission; cells were depleted from seven using an anti-CD19...
Busulfan (Bu) is commonly used as a component of conditioning regimens for hematopoietic stem cell transplantation. Precise delivery the oral formulation compromised by erratic gastrointestinal absorption. An IV Bu was developed to provide dose assurance and complete bioavailability. In phase I study, plasma bioequivalence established at approximately 80% dose. We now report findings first II in which 61 adults with hematologic cancers were treated Bu-cyclophosphamide (BuCy) regimen...
The effect of anoxia on the mitochondrial transmembrane potential and pH gradient was studied in a preparation isolated hepatocytes. Transmembrane (delta psi) calculated from distribution triphenylmethylphosphonium between mitochondrial, cytosolic, extracellular compartments, which were separated by digitonin fractionation centrifugation. Mitochondrial cytosolic values weak acid, dimethadione, determined similarly. After 30 min anoxia, magnitude delta psi decreased -163 to -133 mV...
Patients with steroid-resistant acute graft versus host disease (aGVHD) have a dismal prognosis, mortality rates in excess of 90%. We sought to identify subgroup patients less likely benefit from initial therapy corticosteroids as well the impact response on day 14 outcome. Retrospective evaluation was performed biopsy-proven aGVHD treated after allogeneic HSCT at M.D. Anderson Cancer Center 1998 through 2002 (N = 287). Overall first-line 56%. Grade III-IV and hyperacute GVHD were most...